Trial of Parkinson's And Zoledronic Acid

Key facts

Sponsor

California Pacific Medical Center Research Institute

Principal Investigator

Steve Cummings, MD

CPMC Research Institute

Intervention

Zoledronic Acid 5Mg/Bag 100Ml Inj(drug)

Enrollment

2650 enrolled

Eligibility

60 years · All sexes

Timeline

2019 – 2025

Study locations (30)

• Mayo Clinic, Scottsdale, Arizona, United States
• Washington Regional Medical Center, Fayetteville, Arkansas, United States
• University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Sutter Health, Berkeley, California, United States
• Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
• University of California, Irvine, Irvine, California, United States
• Loma Linda University, Loma Linda, California, United States
• Cedars-Sinai Medical Center, Los Angeles, California, United States
• University of California, Los Angeles, Los Angeles, California, United States
• Valley Parkinson Clinic, Los Gatos, California, United States
• Parkinson's Disease and Movement Disorder Center of Silicon Valley, Palo Alto, California, United States
• University of California, Riverside, Riverside, California, United States
• Sutter Health, Sacramento, California, United States
• University of California, Davis, Sacramento, California, United States
• University of California, San Francisco, San Francisco, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Institute on Aging (NIA) · University of California, San Francisco · Duke University · University of Pittsburgh · Parkinson's Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07509125
  Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
  Universitaire Ziekenhuizen KU Leuven
• RECRUITINGEARLY PHASE1NCT07348276
  First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
  Invicro
• RECRUITINGNANCT07291687
  tDCS as Treatment for Motor Function
  Baycrest
• ACTIVE NOT RECRUITINGNANCT06588673
  Art Therapy in Progressive Supranuclear Palsy
  Vanderbilt University Medical Center
• ENROLLING BY INVITATIONNANCT06597071
  Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
  NeuraLight
• ACTIVE NOT RECRUITINGPHASE2NCT06355531
  A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
  Ferrer Internacional S.A.
• RECRUITINGNCT06949865
  AI-Enhanced Optimization of Acute Levodopa Challenge Test
  Beijing Tiantan Hospital
• RECRUITINGNANCT06174948
  The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders
  Queen Mary University of London

See all trials for Classic progressive supranuclear palsy syndrome →